Bayer Pharma Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Aktiengesellschaft

Schering Aktiengesellschaft

Dana-farber-cancer Institute Inc.

The Broad Institute, Inc.

Bayer Schering Pharma Ag

Schring Aktiengesellschaft

Volker Schulze

Philip Lienau

Knut Eis

Gerhard Siemeister

Ulf Bömer

Antje Margret Wengner

Hans Briem

Detlev Sülzle

Dirk Kosemund

Kirstin Petersen

Ludwig Zorn

Simon Holton

Florian Puehler

Benjamin Bader

Andrea Hägebarth

Anne Mengel

Marcus Koppitz

Detlef Stöckigt

Ulrich Klar

Arwed Cleve

Hartmut Schirok

Wilhelm Bone

Jens Hoffmann

Marion Hitchcock

Dieter Zopf

Mark Jean Gnoth

Amaury Ernesto Fernandez-Montalvan

Clara Christ

Olaf Prien

Karsten Parczyk

Hans-Georg Lerchen

Franz-Josef Mais

Ulrich Lücking

Markus Berger

Lars Bärfacker

Matthew Meyerson

Norbert Schmees

Damian O Arnaiz

Ursula Mönning

Helmut Sonnenschein

Tobias Marquardt

Ingo Hartung

Keith Graham

Ursula Krenz

Donald Bierer

Stefan Kaulfuss

Holger Hess-Stumpp

Heidi Greulich

Lars Wortmann

Stephan Siegel

Heinz Graubaum

Bernard Jacques Haendler

Laura Furst

Stefan Prechtl

Jens Schröder

Roman Hillig

Vera Pütter

Michael Brüning

Christoph Huwe

Tobias Heinrich

Julien Lefranc

Detlev Suelzle

Dieter Moosmayer

Niels Böhnke

Andreas Reichel

Jörg Fanghänel

Cornelia Preusse

René Tempel

Horst Irlbacher

Ulrike Rauh

Franziska Siegel

Michael Niehues

Jozsef Bálint

Uwe Eberspächer

Daniel Korr

Steven Corsello

Steven M Corsello

Bethany Kaplan

Christian Lechner

Ildikó Terebesi

Uwe Eberspaecher

Helmut Morack

Florian Prinz

Amael Madec

Adelaide Clara Faria Alvares De Lemos

Katarzyna Handing

Alisha Caliman

Hassan Youssef Harb

Joszef Bálint

Jérémie Xavier G Mortier

Phi Manh Dinh

Mrinal Shekhar

Florian Pühler

David Mckinney

Kartarzyna Handing

Jérémie Mortier

Eis Knut

Ulf BÖMER

The present invention relates to compounds of formula (I) processes for their production and their use as pharmaceuticals. The compounds are inhibitors of Casein kinase 1 alpha and/or delta (CSNK1α and/or β) useful for the treatment of proliferative disorders.

3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors

Compounds of formula (I) processes for their production and their use as pharmaceuticals. 

4H-pyrrolo[3,2-c]pyridin-4-one derivatives

The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients. 

Heteroarylbenzimidazole compounds

Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.

Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases

Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals. 

3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones

Compound of formula (I), processes for their production and their use as pharmaceuticals. 

4H-pyrrolo[3,2-C]pyridin-4-one derivatives

Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases

The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I): in which A, E, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders

The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I), in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Aminoimidazopyridazines

The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I), in which A, R1, R2, R3, R4, R5 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Amino-substituted imidazopyridazines

The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I): in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Amidoimidazopyridazines as MKNK-1 kinase inhibitors

The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors: Formula (I), in which R, R, R, R, and Rare as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis proliferative of diseases, as well as to intermediate compounds useful in the preparation of said compounds. 

Triazolopyridines

The present invention relates to substituted triazolopyridine compounds of general formula (I); in which R, R, R, R, and Rare as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds. 

Substituted triazolopyridines

The present invention relates to substituted triazolopyridine compounds of general formula (I): in which R, R, R, R, and Rare as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

Substituted triazolopyridines and their use as TTK inhibitors

The present invention relates to amino-substituted imidazopyndazine compounds of general formula (I): in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Growing community of inventors

OT Bergf, Germany

Volker Schulze